29/04/2022 • Live on your screen

Better Methods, Better Evidence, Better Decisions

The conference brings together every year more than 400 delegates working in the healthcare sector, while important international and Greek Academics, market executives and representatives of institutions, the State and patients actively participate in the proceedings.

The conference throughout the years of its organization has become a single meeting point of the market access community facilitating the exchange of views, best practices and recent developments in the field of assessment and negotiation of health technologies in Greece and Europe.


The Conference


The main theme of the 2022 HTA conference is the new role that HTA and Negotiations are called upon to take on, in the context of new EU Regulation on Health Technology Assessment which will allow vital and innovative health technologies – such as innovative medicines, certain medical devices, medical equipment and prevention and treatment methods – to be more widely available. To this end, we have to work together for better methods and allow for better evidence in order to facilitate decision making.

In addition, the role of HTA and Negotiations Committee in health policy as primarily a tool for setting priorities, allocating resources, budgeting, and re-evaluating/ re-negotiating, in an ever-changing environment, with digital technologies and big data promising access to data that will lead to greater transparency and better-informed decisions.

The conference will offer an opportunity to discuss in depth the strategies, procedures, skills and capabilities needed to address challenges and overcome potential barriers to access to many new and innovative therapies.

Last but not least, after 4 years of operation of the HTA Committee and the Drug Price Negotiation Committee, it is the right time to take a look back and reference to their difficulties, challenges and achievements as well as to assess the impact of these reforms on Greece’s pharmaceutical policy.

Meet the

Scientific Committee


Panos Kanavos, PhD, Associate Professor of International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG).


Dimitrios Athanasiou, EMA Pediatric Committee, EPF, WDO, Greek Patients Association Board Member
Nikos Dedes, President, Greek Patients Association
Mary Geitona, Professor in Health Economics, University of Peloponnese [email protected]
Daphne Kaitelidou, Associate Professor in Public Health, Dept. of Nursing, National and Kapodistrian University of Athens [email protected]
Vilma Karagianni, Associate Professor, Director of the Research Laboratory of Statistical Modelling and Educational Technology in Public and Environmental Hygiene, Dept. of Public and Community Health, University of West Attica, Athens
Saridaki – Zoras Zenia, MD PhD Medical Oncologist
President of the BoD of the Hellenic Society of Medical Oncology (HeSMO) Director at the 1st Oncology Dept. Metropolitan Hospital, Athens
Scientific Director of the Oncology Department “Asklepios DIAGNOSIS” Heraklion Crete
Kyriakos Souliotis, Dean of the School of Social & Political Sciences, Professor of Health Policy at the University of Peloponnese
Ioannis Tountas, Professor of Social & Preventive Medicine in the Medical School- University of Athens
Athanasios Vozikis, Associate Professor, Director of the Laboratory of Health Economics and Management (LabHEM), University of Piraeus, Department of Economics
Ioannis Yfantopoulos, Professor of Health Economics and Social Policy, Department of Political Science and Public Administration, National Kapodistrian University of Athens

Meet the



Minister of Health, Ministry of Health, Greece


President HTA Committee, Assoc. Professor Of Pediatrics – Adolescent Medicine, NKUA


PhD, Assoc. Professor of International Health Policy, Assoc. Director LSE Health, LSE

Madeleine HAIG

Research Associate, Medical Technology Research Group, London School of Economics and Political Science (LSE)

Kristian KIDHOLM

Prof. Ηealth Care Innovation, CIMT, Nat. Danish Treatment Council, Head Of HTA Odense Univ. Hospital


Founder & CEO, Data for Patients


Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia


President and Founder of CyberActa, Inc.


President, Pharma Innovation Forum (PIF)


EMA Pediatric Committee, EPF, WDO, GPA Board Member


PhD, Health & Value Lead, Pfizer


President, Hellenic Patients Association (EAE)

Athanasios FILIPPOU

PharmD, MSc, EU Health Parliament, Dept. of Pharmaceutical Planning & Dispensing of Medicines, EOPYY

Dimitrios FILIPPOU

President of the National Medicines Organization (EOF), President of the Medicines Negotiations Committee, Assistant Professor of Anatomy, NKUA


Head of HTA, IQVIA Hellas


Pharmacist, Special Advisor of Pharmaceutical Policy to the Minister of Health


Doctor, Scientific Associate, Therapeutic Clinic of the Medical School, NKUA


Assist. Professor of Research Methodology, Faculty of Health Sciences, University of Peloponnese


CEO of MYO Health, Judge and Mentor for health technology, MITΕF (MIT University), Reviewer for health technology, Horizon and EIC Accelerator funds, European Commission


MSc Molecular Biologist, Scientific Associate of MDA Hellas


Market Access & External Relations Director at AbbVie


President, SFEE & General Manager, Novo Nordisk Hellas


MD, MSc, PhD, Cardiologist / HTA Consultant, Scientific Director of HealThink, Greece


Assoc. Professor of Hygiene, Social and Preventive Medicine, School of Medicine, Aristotle University of Thessaloniki

Declan NOONE, President of the European Haemophilia Consortium (EHC)

Panagiotis BOGIATZIDIS, Governor of the 3rd Health District of Macedonia

Ioannis BOUKOVINAS, Medical Oncologist, Head BIOCLINIC Oncology Unit, Thessaloniki

Konstantinos CHAMBIDIS, Chief of Staff, Ministry of Digital Governance

Mary GEITONA, BSc, Ph.D. Professor in Health Economics, University of Peloponnese

Markos OLLANDEZOS, Director of Scientific Affairs, Panhellenic Pharmaceutical Association (PEF)

Vasilios PENTAFRAGAS, Executive Director, Panhellenic Pharmaceutical Association (PEF)

Stergiani (Stella) SPYROUDirector of IT, 3d Regional Health District of Macedonia 

Yannis YFANTOPOULOS, Professor of Health Economics and Social Policy, Department of Political Science and Public Administration, NKUA

Key Sessions will focus on:

  • Health Technology Assessment: New ways to improve access to innovative technologies
  • Medicines Negotiation Process: New ways to improve access to innovative technologies
  • Using real-world evidence to inform healthcare decision-making (Registries, electronic health records (EHRs), lab tests, wearable devices)
  • Patient – centricity in decision making for better healthcare outcomes
  • HTA frameworks & HCS policies to improve access for Digital Platforms and Medical Devices
Health Technology Assessment: New ways to improve access to innovative technologies
  • The Regulation on Health Technology Assessment, a key deliverable of the European Pharmaceutical Strategy
  • Value Frameworks for HTA
  • HTA committee performance in Greece and future strategy
  • Methods and criteria followed by the Greek HTA: what worked well, and which are the areas for improvement   
Medicines Negotiation Process: New ways to improve access to innovative technologies
  • Medicines Negotiation Committee performance in Greece and future strategy
  • Implementation of Managed Entry Agreements: practical experience and local challenges
  • Medicines negotiation committee as a tool for optimizing pharmaceutical expenditure (i.e disinvestments, reassessments etc)
Using real-world evidence to inform healthcare decision-making (Registries, electronic health records (EHRs), lab tests, wearable devices)
  • RWE as complement to RCTs to strengthen evidence packages
  • Benefits and limitations of using RWE as the only source of data (i.e in rare diseases)
  • How technology can help the gathering of RWD
  • How European regulators and HTA bodies leverage RWE to bring innovative treatments faster (i.e France’s Haute Autorité de Santé (HAS), which recently issued updated guidance that includes the need for RWD in evaluations)
  • Real-time data on utilization and outcomes of new treatments enabling more rapid technology assessment that adapts health services to evolving disease situations and patient needs
  • Best practices from abroad
Patient – centricity in decision making for better healthcare outcomes
  • Current Status of Patient Involvement and Trends in HTA process
  • Impact of Patient Involvement and Good Practices
  • Recommendations for meaningful Patient Involvement in HTA
  • Importance of Social Value Judgements in the HTA process
HTA frameworks & HCS policies to improve access for Digital Platforms and Medical Devices
  • Experience of HTA for Medical Devices in France, Belgium and Austria
  • Germany’s DIGA Regulatory Process for the Marketing and Authorization of Medical Devices
  • European Commission’s Directives

Who should Attend?

  • Healthcare Stakeholders
  • Government representatives
  • Pharmaceutical industry executives (Market Access, Government Affairs, Health Economics)
  • Public & Private Health services providers
  • Health economists
  • Academics
  • Physicians
  • Patient advocates & patient group representatives




AbbVie is a global research-driven biopharmaceutical company. We are committed to developing innovative advanced therapies for some of the world’s most complex and serious health issues. AbbVie’s mission is to leverage our experience, dedicated people and unique approach to innovation to significantly improve treatments across five therapeutic areas: Immunology, Hematology, Eye Care, Neuroscience and Aesthetics. More than 47,000 AbbVie employees around the world work daily to develop therapeutic options for patients worldwide.

In Greece, AbbVie since its inception in 2013, has been operating, apart from the commercial branch, an international clinical research hub. The Site Management & Monitoring Operations hub is responsible for a cluster of 14 countries from Europe, Middle East and Africa, and employs more than 40 scientists from different fields. This allows AbbVie to conduct more than 45 clinical studies in our country in a total investment of over 2.5 million € on an annual basis.

Econcare is a research and consulting firm, specialized in health economics and real-world evidence. Our multidisciplinary, dedicated team has extensive experience in HEOR studies and HTA submissions, across all major therapeutic areas. Our main services include economic modeling, strategic market access, development of HTA submission dossier, evidence synthesis (systematic literature review, network meta-analysis) and real-world evidence generation and analysis.

Inspired by the synthesis of the key-words Health, IT and Think, HealThink was founded to provide high-class health technology assessment (HTA) and research services in the health sector. Based on the long experience of its co-founder/Scientific Director, Dr Panos Stafylas, on Medical/Scientific Coordination of HTA and Digital Health projects, a multidisciplinary team of professionals with diverse scientific background has been created, able to respond to highly demanding projects. HealThink’s experience in HTA of innovative medicines, medical devices and digital health solutions, but also in outcomes research, RWD and data analytics, has led to long-term and extensive collaboration with pharmaceutical industry, research/academic institutes, scientific societies, European consortia and other public or private organizations, both locally and internationally. Website:

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Solutions are powered by the IQVIA CORE™, which combines big data, advanced technology, analytics and extensive industry knowledge. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 70,000 employees worldwide. Learn more at

MYO Health is a full service HEOR consultancy delivering HTA, reimbursement and market access solutions internationally since 2004. We have prepared numerous submissions for new drugs and medical devices in the US and we leverage this experience to optimize HTA submissions for our clients in Greece, as well as to develop practical and improved RWE solutions to boost their value dossiers. With an expert team that combines backgrounds in health economics, medical statistics, epidemiology, health policy and medicine we bring to HTA submissions HEOR capabilities combined with high-quality clinical consulting. For more information visit

Στη Pfizer έχουμε ως σκοπό να «Καινοτομούμε για να αλλάξουμε τις ζωές των ασθενών» και γι’ αυτό επενδύουμε διαρκώς στην εξέλιξη της επιστήμης, και της τεχνολογίας. Η Pfizer Hellas ιδρύθηκε το 1960 και σήμερα απασχολεί 436 εργαζόμενους (Μάρτιος 2021). Έχει πιστοποιηθεί ως Great Place To Work, ενώ έχει αποσπάσει σημαντικές διακρίσεις για την Κοινωνική της προσφορά. Βασικό συστατικό της εταιρικής μας κουλτούρας αποτελεί η αποδοχή της διαφορετικότητας και η ισότιμη αντιμετώπιση όλων. Η Pfizer επενδύει και στηρίζει έμπρακτα το ανθρώπινο δυναμικό και τα ταλέντα της χώρας ιδρύοντας στη Θεσσαλονίκη δυο παγκόσμια κέντρα: το Παγκόσμιο Κέντρο Ψηφιακής Tεχνολογίας (Global Digital and Technology Hub) και το Κέντρο Επιχειρησιακών Λειτουργιών και Υπηρεσιών.


ELPEN has been active for 56 years in the production of branded Greek medicines. With 1,100 employees at group level, the company invests more than 10% of its annual turnover in research projects. In 1996 ELPEN founded its Experimental, Research & Training Center. ELPEN is highly recognized in international markets with exports of 30 medical products in 18 European countries and 41 worldwide.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.

We remain committed to our core values, Integrity, Fairness, Honesty and Perseverance, always putting patients at the center of everything we do.

Under the Auspices

Media Sponsors

Media Partner

Livestreaming by

CONEQ provides technical equipment and services to any kind of event. With our Simultaneous Interpretation Systems, Conference Systems, AudioVisual Equipment we support events and provide the best service to our customers. Our professionalism, our high quality of service and state of the art equipment offered to over 600 large and of great significance conferences during the last 5 years have certainly contributed to our constant uptrend. Call us at (+30) 211 2163453. or email us at [email protected]

Organized by

Contact us

Sponsorships & Registrations
Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]

Natalia Toubanaki, T: +30 210 6617 777 (ext. 289), +306947936708, E: [email protected]
Valya Kyritsi, T: +30 210 6617 777 (ext. 227), E: [email protected]


  338. Kleisthenous Str. 15344, Gerakas, Attiki, Greece
  +30 210 6617777
  +30 210 6617778